Kawasaki Disease Research Center, Department of Pediatrics, University of California San Diego, La Jolla, CA, USA.
Section of Paediatric Infectious Disease, Department of Infectious Disease, Imperial College London, London, UK.
Lancet Child Adolesc Health. 2023 Oct;7(10):697-707. doi: 10.1016/S2352-4642(23)00166-9. Epub 2023 Aug 17.
Although Kawasaki disease is commonly regarded as a single disease entity, variability in clinical manifestations and disease outcome has been recognised. We aimed to use a data-driven approach to identify clinical subgroups.
We analysed clinical data from patients with Kawasaki disease diagnosed at Rady Children's Hospital (San Diego, CA, USA) between Jan 1, 2002, and June 30, 2022. Patients were grouped by hierarchical clustering on principal components with k-means parcellation based on 14 variables, including age at onset, ten laboratory test results, day of illness at the first intravenous immunoglobulin infusion, and normalised echocardiographic measures of coronary artery diameters at diagnosis. We also analysed the seasonality and Kawasaki disease incidence from 2002 to 2019 by subgroup. To explore the biological underpinnings of identified subgroups, we did differential abundance analysis on proteomic data of 6481 proteins from 32 patients with Kawasaki disease and 24 healthy children, using linear regression models that controlled for age and sex.
Among 1016 patients with complete data in the final analysis, four subgroups were identified with distinct clinical features: (1) hepatobiliary involvement with elevated alanine transaminase, gamma-glutamyl transferase, and total bilirubin levels, lowest coronary artery aneurysm but highest intravenous immunoglobulin resistance rates (n=157); (2) highest band neutrophil count and Kawasaki disease shock rate (n=231); (3) cervical lymphadenopathy with high markers of inflammation (erythrocyte sedimentation rate, C-reactive protein, white blood cell, and platelet counts) and lowest age-adjusted haemoglobin Z scores (n=315); and (4) young age at onset with highest coronary artery aneurysm but lowest intravenous immunoglobulin resistance rates (n=313). The subgroups had distinct seasonal and incidence trajectories. In addition, the subgroups shared 211 differential abundance proteins while many proteins were unique to a subgroup.
Our data-driven analysis provides insight into the heterogeneity of Kawasaki disease, and supports the existence of distinct subgroups with important implications for clinical management and research design and interpretation.
US National Institutes of Health and the Irving and Francine Suknow Foundation.
虽然川崎病通常被认为是一种单一的疾病实体,但已认识到其临床表现和疾病结局存在变异性。我们旨在使用数据驱动的方法来识别临床亚组。
我们分析了 2002 年 1 月 1 日至 2022 年 6 月 30 日期间在 Rady 儿童医院(圣地亚哥,加利福尼亚州,美国)诊断为川崎病的患者的临床数据。患者根据 14 个变量(包括发病年龄、十种实验室检查结果、首次静脉注射免疫球蛋白时的疾病天数以及诊断时冠状动脉直径的正常化超声心动图测量值),通过主成分的层次聚类和基于 k-均值的分区进行分组。我们还按亚组分析了 2002 年至 2019 年的季节性和川崎病发病率。为了探索确定的亚组的生物学基础,我们使用控制年龄和性别的线性回归模型,对 32 名川崎病患者和 24 名健康儿童的 6481 种蛋白质的蛋白质组学数据进行了差异丰度分析。
在最终分析中,1016 名患者中有 4 个亚组具有不同的临床特征:(1)肝胆汁淤积,表现为丙氨酸转氨酶、γ-谷氨酰转移酶和总胆红素水平升高,最低的冠状动脉瘤但最高的静脉注射免疫球蛋白抵抗率(n=157);(2)最高的带中性粒细胞计数和川崎病休克率(n=231);(3)颈淋巴结病,炎症标志物高(红细胞沉降率、C 反应蛋白、白细胞和血小板计数),年龄调整血红蛋白 Z 评分最低(n=315);(4)发病年龄小,冠状动脉瘤最高,但静脉注射免疫球蛋白抵抗率最低(n=313)。这些亚组具有不同的季节性和发病轨迹。此外,亚组之间共享 211 个差异丰度蛋白,而许多蛋白是亚组特有的。
我们的数据驱动分析提供了对川崎病异质性的深入了解,并支持存在具有重要临床管理和研究设计和解释意义的不同亚组。
美国国立卫生研究院和 Irving 和 Francine Suknow 基金会。